Kindred Biosciences to Present Pivotal Data on Zimeta

November 29, 2016

Kindred Biosciences, Inc., a biopharmaceutical company focused on saving and improving the lives of pets, announced today that Emily Sundman, DVM, clinical development scientist for KindredBio, will present pivotal effectiveness data for Zimeta™ (dipyrone injection) at the American Association of Equine Practitioners (AAEP) Convention in Orlando, Florida, on Tuesday, December 6, 2016, at 8:25 a.m. ET as part of the Internal Medicine track. The presentation will be available at www.kindredbio.com/investor-relations/events/ following the AAEP presentation.

Zimeta is a pyrazolone anti-inflammatory drug with a unique mechanism of action that is under development for the control of pyrexia (fever) in horses. The application for Zimeta is currently under review at the FDA Center for Veterinary Medicine (CVM). Approval and launch of the drug is expected in 2017. 

Share This Story On:

Stockroom //
New Products

Digital Guide

CBD Trends

This digital guide provides valuable information on the subject of CBD, including content on dosage and the importance of being fully transparent about the product’s origin

Dog & Cat Needs

With dogs and cats being members of the family, there's vital information to know in order to serve their pet parents.

Pet Nutrition

Discover how science, technology and pet owning lifestyles are changing the industry.

Pet Parenting

This digital guide dives into the human-animal bond, and the roles that pet parents play in the development of their companion animals.

Enews Subscribe

Subscribe To Pet Age
Sign up for the weekly e-newsletter, print magazine and more. Sign Up